Influence of melatonin on blood pressure indicators with different severity of desynchronosis

Purpose. To study the dynamics of blood pressure (BP) indicators under the influence of exogenously administered melatonin (Melatonin-SZ, Severnaya Zvezda, Russia) with various manifestations of desynchronosis of circadian BP rhythms (arterial hypertension – AH, high normal blood pressure) to determine the scheme of their effective compensation. Material and methods. The study included 101 patients with desynchronosis of circadian rhythms of blood pressure – 52 patients with hypertension, constituting the first and second groups, and 49 individuals with high normal blood pressure, representing the third and fourth groups. Patients of the second and fourth groups received conservative therapy, patients of the first and third groups combined it with melatonin. All patients underwent measurements of office blood pressure, home monitoring of blood pressure (ABPM), electrocardiography, 24-hour blood pressure monitoring (ABPM). Results and discussion. In patients of the first and third groups, compared with the traditional treatment groups, by the end of the observation period, a significantly (p < 0.05) decrease in office systolic blood pressure (SBP) / diastolic blood pressure (DBP) was established: in the first group compared with the second – 1.11 / 1.13 times, in the third group compared to the fourth – 1.43 / 1.58 times; significantly more (p < 0.05) pronounced decrease in SBP / DBP during DMAD – by 1.08 / 1.17 and 1.58 / 1.62 times, respectively, Significantly (p < 0.05) more pronounced decrease in average daily, average daily and average nighttime SBP / DBP during ABPM – by 1.13 / 1.20, 1.11 / 1.20, 1.23 / 1.25 and 1.47 / 1.31, 1.42 / 1.19, 1.54 / 1.41 times, respectively; reliably (p < 0.05) more frequent registration of the dipper rhythm type SBP / DBP – 1.6 / 1.4 and 1.6 / 1.4 times, respectively. In addition, the dynamics of patients in the first and third groups showed a significant (p < 0.05) decrease in the mean daily and mean nighttime SBP / DBP variability (SBP in the first group by 27.3 and 41.3 %, respectively; DBP in the first group by 20.1 and 26.3 %, respectively; SBP in the third group by 13.5 and 25.2 %, respectively; DBP in the third group by 12.2 and 28.2 %, respectively). Conclusions. With various manifestations of desynchronosis of circadian rhythms of blood pressure (AH, high normal blood pressure), the prescription of melatonin (Melatonin-SZ, Severnaya Zvezda, Russia) at a dose of 3 mg per day 30–40 minutes before bedtime for a month against the background of non-drug therapy and antihypertensive drugs led to a significantly more effective decrease in blood pressure at its office measurement, DMAD, ABPM with an improvement in the circadian rhythm of blood pressure and normalization of blood pressure variability.

1. Oransky I. E., Tsarfis P. G. Biorhythmology and chronotherapy (chronobiology and chronobalneophysiotherapy). M.: Higher school, 1989; 159 р.

2. Alyakrinsky B. S. Biological rhythms and organization of human life in space. – M.: The science, 1983; Vol. 46: 248 p. (Series: Problems of Space Biology).

3. Nesterova M. V. Melatonin is an adaptogen with multimodal action. Meditsinskiy sovet. 2015; 18: 50–53. [Russian: Нестерова М. В. Мелатонин – адаптоген с мультимодальными возможностями. Медицинский совет. 2015; 18: 50–53]. DOI: https://doi.org/10.21518/2079-701X-2015-18-50-53.

4. Naumov A. V., Konyukh E. A. Melatonin: biomedical functions. Health and environmental issues. 2011; 3 (29): 132–136.

5. Vasendin D. V. Biomedical effects of melatonin: some results and prospects of study. Bulletin of the Russian Military Medical Academy. 2016; 3 (55): 171–178.

6. Pyatin V. F., Romanchuk N. P., Volobuev A. N. Circadian control of the brain-microbiota neural network. Bulletin of science and practice. 2018; 4 (11): 69–90.

7. Chazova I. E., Zhernakova Yu.V. on behalf of experts. Clinical recommendations. Diagnosis and treatment of arterial hypertension. Systemic hypertension. 2019; 16 (1): 6–31.

8. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018; 39 (33): 3021–3104. DOI: 10.1093/eurheartj/ehy339.

9. Borisenok O. A., Bushma K. M. The biological role of melatonin and the clinically important effects of its combination with xenobiotics. Medical news. 2011; 1: 26–30.

10. Schernhammer E. S., Kroenke C. H., Dowsett М., Folkerd E., Hankinson S.E Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. Journal of Pineal Research. 2006; 40 (2): 116–124. DOI: https://doi.org/10.1111/j.1600-079X.2005.00285.x.

11. Arterial hypertension in adults. Clinical recommendations of the Ministry of Health of the Russian Federation, 2020; 162 р. Available on: http://cr.rosminzdrav.ru/#!/recomend/687.

12. Tobacco dependence syndrome, adult tobacco withdrawal syndrome. Clinical recommendations of the Ministry of Health of the Russian Federation, 2018; 53 р. Available on: http://cr.rosminzdrav.ru/#!/recomend/907.

13. Dedov I. I., Melnichenko G. A., Shestakova M. V., Troshina E. A., Mazurina N. V., Shestakova E. A. et al. Morbid obesity treatment in adults. Obesity and metabolism. 2018; 15 (1): 53–70.

14. Antonov V. N. Etiological and clinical aspects of manifestation the various variants of chronic obstructive pulmonary disease course. Siberian Medical Review. 2017; 5: 35–40.

15. Gassan D. A., Naumov D. E., Kotova O. O., Prikhodko A. G., Kolosov V. P. TRPM8 gene polymorphism and smoking as the factors of severe bronchial obstruction in patients with asthma. Bulletin physiology and pathology of respiration. 2017; 1 (65): 24–30.

16. Doshchitsin V. L. Guide to рractical еlectrocardiography. – M.: MEDpress-Inform, 2015; 416 р.

17. Parati G., Stergiou G., O’Brien E., Asmar R., Beilin L., Bilo G. et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. Journal of Hypertension. 2014; 32 (7): 1359–1366. DOI: 10.1097/HJH.0000000000000221.

18. Vodop’yanova O.A., Moiseeva I. Ya., Rodina O.P, Kustikova I. N., Antropova N. V. The influence of cytoflavin and cardioxipin on the parameters of 24-hour arterial pressure monitoring in patients with chronic cerebral circulation insufficiency, arterial hypertension and hypercholesterolemia. Clinical medicine. 2015; 93 (2): 67–71.

19. Sewerynek Е. Melatonin and the cardiovascular system. Neuroеndocrinology Letters. 2002; 23 (Suppl. 1): 79–83

20. Kawashima K., Miwa Y., Fujimoto K., Oohata H., Nishino H., Koike H. Antihypertensive action of melatonin in the spontaneously hypertensive rat. Clinical and Experimental Hypertension. 1987; 9 (7): 1121–1131. DOI: 10.3109/10641968709160037.

21. K-Laflamme A., Wu L., Foucart S., de Champlain J. Impaired basal sympathetic tone and alpha1-adrenergic responsiveness in association with the hypotensive effect of melatonin in spontaneously hypertensive rats. American Journal of Hypertension. 1998; 11 (2): 219–229. DOI: 10.1016/ s0895–7061(97)00401–9.

22. Girouard H., Chulak Ch., LeJossec M., Lamontagne D., de Champlain J. Chronic antioxidant treatment improves sympathetic functions and beta-adrenergic pathway in the spontaneously hypertensive rats. Journal of Hypertension. 2003; 21 (1): 179–188. DOI: 10.1097/00004872–200301000–00028.

23. Arushanyan E. B., Mastyagina O. A. The value of melatonin for the activity of the cardiovascular system and its pharmacological regulation. Experimental and Clinical Pharmacology. 2008; 71 (3): 65–71.

24. Arushanyan E. B. The universal therapeutic potential of melatonin. Clinical medicine. 2013; 2: 4–8.

25. Kislyak O. A., Postnikova S. L., Kopelev A. A. Assessment of blood pressure variability and its decrease at nighttime in the program ORIGINAL. Consilium Medicum. 2011; 13 (10): 29–32.